Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
The outcome of steroid-dependent or frequently relapsing nephrotic syndrome of minimal change disease (MCD), mesangial proliferative GN (MesGN), or FSGS may be poor and with major treatment toxicity. This academic, multicenter, off-on trial (ClinicalTrials.gov #NCT00981838) primarily evaluated the effects of rituximab therapy followed by immunosuppression withdrawal on disease recurrence in 10 children and 20 adults with MCD/MesGN (n=22) or FSGS who had suffered ≥2 recurrences over the previous year and were in steroid-induced remission for ≥1 month. Participants received one dose (n=28) or two doses of rituximab (375 mg/m(2) intravenously). At 1 year, all patients were in remission: 18 were treatment-free and 15 never relapsed. Compared with the year before rituximab treatment, total relapses decreased from 88 to 22 and the per-patient median number of relapses decreased from 2.5 (interquartile range [IQR], 2-4) to 0.5 (IQR, 0-1; P<0.001) during 1 year of follow-up. Reduction was significant across subgroups (children, adults, MCD/MesGN, and FSGS; P<0.01). After rituximab, the per-patient steroid maintenance median dose decreased from 0.27 mg/kg (IQR, 0.19-0.60) to 0 mg/kg (IQR, 0-0.23) (P<0.001), and the median cumulative dose to achieve relapse remission decreased from 19.5 mg/kg (IQR, 13.0-29.2) to 0.5 mg/kg (IQR, 0-9.4) (P<0.001). Furthermore, the mean estimated GFR increased from 111.3±25.7 to 121.8±29.2 ml/min per 1.73 m(2) (P=0.01), with the largest increases in children and in FSGS subgroups. The mean height z score slope stabilized in children (P<0.01). Treatment was well tolerated. Rituximab effectively and safely prevented recurrences and reduced the need for immunosuppression in steroid-dependent or frequently relapsing nephrotic syndrome, and halted disease-associated growth deficit in children.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Tanner, J. M., & Whitehouse, R. H. (1976) · Archives of Disease in Childhood · doi:10.1136/adc.51.3.170 · Cited by 3,137
McLaughlin, P., Grillo-López, A. J., Link, B. K., Levy, R., Czuczman, M. S., Williams, M. E., Heyman, M. R., Bence-Bruckler, I., White, C. A., Cabanillas, F., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2825 · Cited by 2,755
Schwartz, G. J., Brion, L. P., & Spitzer, A. (1987) · Pediatric Clinics of North America · doi:10.1016/s0031-3955(16)36251-4 · Cited by 1,726
The use of fractional polynomials to model continuous risk variables in epidemiology
Royston, P., Ambler, G., & Sauerbrei, W. (1999) · International Journal of Epidemiology · doi:10.1093/ije/28.5.964 · Cited by 1,066
Rituximab-Induced Depletion of Anti-PLA2R Autoantibodies Predicts Response in Membranous Nephropathy
Beck, L. H., Fervenza, F. C., Beck, D. M., Bonegio, R. G. B., Malik, F. A., Erickson, S. B., Cosio, F. G., Cattran, D. C., & Salant, D. J. (2011) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010111125 · Cited by 471
Adult Minimal-Change Disease: Clinical Characteristics, Treatment, and Outcomes
Waldman, M., Crew, R. J., Valeri, A., Busch, J., Stokes, B., Markowitz, G., D'Agati, V., & Appel, G. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03531006 · Cited by 420
Hildebrandt, F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60236-x · Cited by 305
Ravani, P., Magnasco, A., Edefonti, A., Murer, L., Rossi, R., Ghio, L., Benetti, E., Scozzola, F., Pasini, A., Dallera, N., et al. (2011) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09421010 · Cited by 207
Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy
Benz, K., D�tsch, J., Rascher, W., & Stachel, D. (2004) · Pediatric Nephrology · doi:10.1007/s00467-004-1434-z · Cited by 206
Cravedi, P., Ruggenenti, P., Sghirlanzoni, M. C., & Remuzzi, G. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.01180307 · Cited by 191
Self-citationRituximab in Children with Resistant Idiopathic Nephrotic Syndrome
Magnasco, A., Ravani, P., Edefonti, A., Murer, L., Ghio, L., Belingheri, M., Benetti, E., Murtas, C., Messina, G., Massella, L., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011080775 · Cited by 174
Self-citationPrecision of plasma clearance of iohexol for estimation of GFR in patients with renal disease.
Gaspari, F., Perico, N., Matalone, M., Signorini, O., Azzollini, N., Mister, M., & Remuzzi, G. (1998) · Journal of the American Society of Nephrology · doi:10.1681/asn.v92310 · Cited by 161
Self-citationRole of the immune system in the pathogenesis of idiopathic nephrotic syndrome
van den Berg, J. G., & Weening, J. J. (2004) · Clinical Science · doi:10.1042/cs20040095 · Cited by 148
François, H., Daugas, É., BENSMAN, A., & Ronco, P. M. (2007) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2006.10.015 · Cited by 107
Rituximab efficiency in children with steroid-dependent nephrotic syndrome
Sellier‐Leclerc, A., Macher, M., Loirat, C., Guérin, V., Watier, H., Peuchmaur, M. M., Baudouin, V., & Deschênes, G. (2010) · Pediatric Nephrology · doi:10.1007/s00467-010-1465-6 · Cited by 94
Winter, M. C., & Hancock, B. W. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330902750114 · Cited by 91
Type D personality and vulnerability to adverse outcomes in heart disease
Denollet, J., & Conraads, V. M. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78.s1.02 · Cited by 89
Effect of single-dose rituximab on steroid-dependent minimal-change nephrotic syndrome in adults
Takei, T., Itabashi, M., Moriyama, T., Kojima, C., Shiohira, S., Shimizu, A., Tsuruta, Y., Ochi, A., Amemiya, N., Mochizuki, T., et al. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs515 · Cited by 82
Long-term linear growth of children with severe steroid-responsive nephrotic syndrome
Emma, F., Sesto, A., & Rizzoni, G. (2003) · Pediatric Nephrology · doi:10.1007/s00467-003-1176-3 · Cited by 76
Self-citationÉlie, V., Fakhoury, M., Deschênes, G., & Jacqz-Aigrain, É. (2011) · Pediatric Nephrology · doi:10.1007/s00467-011-1947-1 · Cited by 69
Pharmacovigilance and PML in the oncology setting
Bennett, C. L. (2011) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.78.s2.04 · Cited by 14
Steroid Sensitive Nephrotic Syndrome
Hodson, E. M., Alexander, S. I., & Graf, N. S. (2016) · Springer eBooks · doi:10.1007/978-3-662-52972-0_15 · Cited by 13
Steroid-Sensitive Nephrotic Syndrome
Hodson, E. M., Alexander, S. I., & Graf, N. (2008) · Elsevier eBooks · doi:10.1016/b978-0-323-04883-5.50021-0 · Cited by 6
Cited by
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
Rovin, B. H., Adler, S. G., Barratt, J., Bridoux, F., Burdge, K. A., Chan, T. M., Cook, H. T., Fervenza, F. C., Gibson, K. L., Glassock, R. J., et al. (2021) · Kidney International · doi:10.1016/j.kint.2021.05.021 · Cited by 2,518
Self-citationKopp, J. B., Anders, H.-J., Susztak, K., Podestà, M. A., Remuzzi, G., Hildebrandt, F., & Romagnani, P. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0196-7 · Cited by 562
Self-citationVivarelli, M., Massella, L., Ruggiero, B., & Emma, F. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05000516 · Cited by 557
Self-citationIijima, K., Sako, M., Nozu, K., Mori, R., Tuchida, N., Kamei, K., Miura, K., Aya, K., Nakanishi, K., Ohtomo, Y., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60541-9 · Cited by 451
Ruggenenti, P., Debiec, H., Ruggiero, B., Chianca, A., Pellé, T., Gaspari, F., Suardi, F., Gagliardini, E., Orisio, S., Benigni, A., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014070640 · Cited by 376
Self-citation
Metadata
- Authors
- Ruggenenti, P., Ruggiero, B., Cravedi, P., Vivarelli, M., Massella, L., Marasà, M., Chianca, A., Rubis, N., Ene-Iordache, B., Rudnicki, M., Pollastro, R. M., Capasso, G., Pisani, A., Pennesi, M., Emma, F., & Remuzzi, G.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2014-04
- Volume
- 25
- Issue
- 4
- Pages
- 850-863
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2124215501
- Cited by
- 267
- References
- 24
- FWCI
- 18.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.